Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie has completed a Phase 1 clinical trial titled ‘A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Single Ascending Dose Trial to Assess the Safety, Tolerability and Pharmacokinetic Effects of ALIA-1758 in Healthy Participants.’ The study aimed to evaluate the safety, tolerability, and pharmacokinetics of ALIA-1758, a new drug administered either intravenously or subcutaneously, in healthy individuals. This trial is significant as it marks the first human testing of ALIA-1758, potentially paving the way for future therapeutic applications.
The intervention tested was ALIA-1758, administered in single ascending doses, with the purpose of assessing its safety and pharmacokinetic profile. A placebo was used as a comparator to ensure the reliability of the results.
The study was designed as a randomized, double-blind, placebo-controlled trial with a parallel intervention model. It involved quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors were all blinded to the treatment allocations. The primary purpose of this study was treatment-focused.
The study commenced on May 9, 2024, and was completed by July 15, 2025. These dates are crucial as they indicate the timeline of the trial’s progress and its recent completion, which is relevant for stakeholders tracking the development of ALIA-1758.
The completion of this study could have significant implications for AbbVie’s stock performance and investor sentiment. Successful results might enhance AbbVie’s position in the pharmaceutical market, potentially impacting its stock positively. Investors should also consider the competitive landscape, as advancements in drug development can influence market dynamics.
The study is now completed, and further details can be accessed on the ClinicalTrials portal.